| Code | CSB-RA723415MB6HU |
| Size | US$9799 |
| Order now | |
| Have Questions? | Leave a Message or Start an on-line Chat |
This recombinant monoclonal antibody is developed as a research-grade biosimilar to IBI-325, targeting NT5E (ecto-5'-nucleotidase), also known as CD73. NT5E is a cell surface enzyme that catalyzes the conversion of extracellular adenosine monophosphate to adenosine, playing a critical role in purinergic signaling and immune regulation. By generating adenosine in the tumor microenvironment, NT5E promotes immunosuppression through inhibition of T cell and natural killer cell function while enhancing regulatory T cell activity. Elevated NT5E expression is associated with multiple cancers, including triple-negative breast cancer, melanoma, and ovarian cancer, where it correlates with poor prognosis and immune evasion.
IBI-325 is a therapeutic antibody designed to block NT5E enzymatic activity, thereby reducing adenosine-mediated immunosuppression and potentially restoring anti-tumor immune responses. This biosimilar provides researchers with a valuable tool for investigating NT5E-mediated immune regulation, tumor microenvironment dynamics, and combination immunotherapy strategies. It supports studies examining checkpoint inhibition mechanisms and adenosine pathway modulation in oncology and immunology research.
There are currently no reviews for this product.